Co-Diagnostics Lifts $10M ATM Cap and Extends Lock-Up, Widening Dilution Risk

summarizeSummary

Co-Diagnostics removed the $10 million cap on its ATM equity program, allowing sales up to the full amount registered under its shelf. The move, alongside a concurrent $7.9 million ATM activation, deepens the dilution risk for a company already facing a going concern warning.

check_boxKey Events · Financing and Capital Events · CODX

• ATM Cap Removed

  The amendment eliminates the previous $10 million aggregate dollar limit on ATM sales, allowing the company to sell shares up to the amount registered under its effective shelf registration statement.

• Concurrent ATM Activation

  This 8-K was filed alongside a prospectus supplement activating a $7.9 million ATM program, meaning the company can now sell shares under the amended agreement immediately.

• Lock-Up Extended

  The company agreed with its May 2026 private placement investors to extend the lock-up period to August 14, 2026, preventing those investors from selling into the ATM sales.

• Dilution Overhang Intensifies

  With the cap removed and a new ATM activated, the potential dilution overhang has increased materially for a company with a market cap of only $10.8 million and a going concern warning.

auto_awesomeAnalysis · CODX · Industrial Applications And Services

By amending its at-the-market equity distribution agreement, Co-Diagnostics removed the previous $10 million aggregate dollar limit on sales, clearing the way to sell shares up to the amount registered and available under its effective shelf registration statement. This change, paired with the concurrent activation of a $7.9 million ATM program, materially expands the potential dilution overhang at a time when the company is burning cash and carries a going concern warning. To facilitate the ATM sales without immediate resale pressure, the company also extended a lock-up period with its May 2026 private placement investors to August 14, 2026.